Dear investor,

On behalf of the entire team, I would like to thank our historical shareholders who took part in this transaction and to the new shareholders who enabled it to be a success. Thanks to these funds, it is with determination that we will be able to accelerate our clinical developments in the treatment of cardiovascular emergencies, which remain a crucial public health challenge. We are proud to be one of the few listed companies in the world which specializes in developing a new drug for ischemic strokes. This focus makes ACTICOR a unique value in the stock market for our shareholders, and we will do everything we can to successfully meet the next stages of our developments.

Gilles AVENARD, Chief Executive Officer of Acticor Biotech